No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GMED240719C67500
- 2.85
- +0.96+50.79%
15min DelayClose Jul 11 16:00 ET
2.85High2.70Low
2.70Open1.89Pre Close2 Volume125 Open Interest67.50Strike Price555.00Turnover27.49%IV-0.57%PremiumJul 19, 2024Expiry Date3.25Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8827Delta0.0674Gamma20.21Leverage Ratio-0.0431Theta0.0133Rho17.84Eff Leverage0.0209Vega
Intraday
- 5D
- Daily
News
Here's Why Globus Medical (GMED) Is a Strong Value Stock
BTIG Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $72
BTIG analyst Ryan Zimmerman maintains $Globus Medical(GMED.US)$ with a buy rating, and maintains the target price at $72.According to TipRanks data, the analyst has a success rate of 46.3% and a total
FDA Clears Orthopedics Robot From Globus Medical
Express News | Globus Medical Inc : RBC Raises Target Price to $76 From $70
RBC Raises Price Target on Globus Medical to $76 From $70, Maintains Outperform Rating
Globus Medical (GMED) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $55 to $85. Price: 66.80, Change: -0.20, Percent Change: -0.30
Globus Medical, Inc.'s (NYSE:GMED) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Globus Medical's (NYSE:GMED) stock is up by a considerable 29% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current sh
Comments
The company's CEO, Dan Scavilla, expressed confidence in Pfeil's ability to drive operational efficiency and deliver profitable growth, especially in light of the ongoing integration following their merger with NuVasive.
Press Release: Globus Medical Promotes Keith Pfeil to Chief Operating Officer and Chief Financial OfficerGlobus Medical's superior earnings outlook is contributing to its high P/E, which shareholders are currently comfortable with, expecting not to face a threat to future earnings. The confidence in the future earnings performance supports the current share price.
Globus Medical's persisting issues impact its valuation and a drop in EPS may spark shareholder worry. The long-term share performance is lackluster, unsettling even potential contrarian investors seeking a turnaround.
Read more